Abstract
T cells are involved in the early identification and clearance of viral infections and also support the development of antibodies by B cells. This central role for T cells makes them a desirable target for assessing the immune response to SARS-CoV-2 infection. Here, we combined two high-throughput immune profiling methods to create a quantitative picture of the T-cell response to SARS-CoV-2. First, at the individual level, we deeply characterized 3 acutely infected and 58 recovered COVID-19 subjects by experimentally mapping their CD8 T-cell response through antigen stimulation to 545 Human Leukocyte Antigen (HLA) class I presented viral peptides (class II data in a forthcoming study). Then, at the population level, we performed T-cell repertoire sequencing on 1,815 samples (from 1,521 COVID-19 subjects) as well as 3,500 controls to identify shared "public" T-cell receptors (TCRs) associated with SARS-CoV-2 infection from both CD8 and CD4 T cells. Collectively, our data reveal that CD8 T-cell responses are often driven by a few immunodominant, HLA-restricted epitopes. As expected, the T-cell response to SARS-CoV-2 peaks about one to two weeks after infection and is detectable for at least several months after recovery. As an application of these data, we trained a classifier to diagnose SARS-CoV-2 infection based solely on TCR sequencing from blood samples, and observed, at 99.8% specificity, high early sensitivity soon after diagnosis (Day 3-7 = 85.1% [95% CI = 79.9-89.7]; Day 8-14 = 94.8% [90.7-98.4]) as well as lasting sensitivity after recovery (Day 29+/convalescent = 95.4% [92.1-98.3]). These results demonstrate an approach to reliably assess the adaptive immune response both soon after viral antigenic exposure (before antibodies are typically detectable) as well as at later time points. This blood-based molecular approach to characterizing the cellular immune response has applications in clinical diagnostics as well as in vaccine development and monitoring.
Competing Interest Statement
TM Snyder, RM Gittelman, M Klinger, DH May, EJ Osborne, R Taniguchi, IM Kaplan, JN Dines, MT Noakes, X Chen, S Elasady, E Svejnoha, P Ebert, M Pesesky, P De Almeida, H O'Donnell, Q DeGottardi, G Keitany, J Lu, A Vong, R Elyanow, P Fields, L Baldo have employment and equity ownership with Adaptive Biotechnologies. HS Robins has employment, equity ownership, patents, and royalties with Adaptive Biotechnologies. HJ Zahid, R Pandya, J Greissl, and JM Carlson have employment and equity ownership with Microsoft. J Heath: Merck managed the funding (from BARDA) for the ISB INCOV project, but had no role in planning the research or in writing the paper. J Martinez-Lopez is a consultant for Adaptive Biotechnologies in projects outside of COVID-19.
Funding Statement
The ISB INCOV study supported by Dept. of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under Contract No. HHSO100201600031C L. D. Notarangelo and H. C. Su are supported by the Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health. Sample collection in Brescia and Pavia was supported by Regione Lombardia, Italy. Sample collections from i+12/CNIO were supported by CRIS foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Multiple sources/review boards: Samples provided by the NIAID were collected under approval by Comitato Etico Provinciale (protocol NP-4000), and by Comitato Etico, Ospedale San Gerardo Monza (protocol COVID-STORM). Samples provided by Hospital 12 de Octubre were collected under approval by Comite Etico del Hospital 12 de Octubre, Madrid IC (protocol 20/161). Samples provided by Swedish-ISB were collected under approval by the Providence St. Joseph's Health system IRB (STUDY2020000175). Samples provided by IRST and AUSL Romagna were collected under approval by CEROM (IRSTB113). Whole blood samples from DLS (Discovery Life Sciences, Huntsville, AL) were collected under Protocol DLS13 for collection of remnant clinical samples. From Bloodworks Northwest (Seattle, WA), volunteer donors recovered from COVID-19 were consented and collected under the Bloodworks Research Donor Collection Protocol BT001. Samples from ImmuneRACE (NCT04494893) were collected under approval from Western Institutional Review Board (WIRB reference number 1-1281891-1, Protocol ADAP-006).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Update includes new data including two additional studies included in analysis. New results section "Direct comparison of T-cell signature with antibody serology" added, including Table 2 and Supporting Figure S4. Other minor revisions and updates to text for readability.
Data Availability
The COVID-19 MIRA data and COVID-19 study immunosequencing data are freely available for analysis and download from the Adaptive Biotechnologies immuneACCESS site at https://clients.adaptivebiotech.com/pub/covid-2020
